Thriftmaster Global Biosciences

Thriftmaster Global Biosciences is a Dallas-based biotechnology company founded in 2019 that specializes in developing innovative cannabinoid-based therapies delivered via its patented metered-dose inhaler, ApelinDx. The company maintains a strategic research partnership with Augusta University, focusing on the therapeutic potential of inhaled cannabidiol (CBD) for severe and orphan conditions such as glioblastoma, Alzheimer's disease, and acute respiratory distress syndrome (ARDS). Their research has demonstrated that inhaled CBD can effectively modulate neuroinflammatory pathways, including the IDO/cGAS and IL-33/TREM2 axes. TGB holds exclusive licensing rights to the intellectual property generated through its academic collaborations and is advancing its pipeline toward human clinical trials. The company's lead programs are currently in the pre-clinical and IND-enabling stages, with a focus on neurological and inflammatory indications.